Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;23(1):e69-e82.
doi: 10.1016/j.cllc.2021.10.009. Epub 2021 Oct 25.

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

Hidetoshi Hayashi  1 , Ernest Nadal  2 , Jhanelle E Gray  3 , Andrea Ardizzoni  4 , Nicola Caria  5 , Tarun Puri  5 , Christian Grohe  6
Affiliations
Free article
Review

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

Hidetoshi Hayashi et al. Clin Lung Cancer. 2022 Jan.
Free article

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are standard of care in the first-line (1L) setting for patients with metastatic non-small cell lung cancer (mNSCLC) with activating EGFR mutations. EGFR-activating mutations are a predictive factor for response to EGFR-TKIs. Meta-analyses have shown that patients with exon 21_L858R mutations exhibit reduced sensitivity to EGFR-TKIs, resulting in inferior patient outcomes compared to those with exon 19 deletion mutations, with worse overall survival, progression-free survival, objective response, and disease control rates. Clinical activity observed with 1L therapy with first-generation (1G), second-generation (2G), and third-generation (3G) EGFR-TKIs is not permanent, and resistance inevitably develops in all cases, supporting the importance of overall treatment planning. The introduction of the 3G EGFR-TKI, osimertinib, provides an opportunity to overcome T790M-mediated resistance to 1G, and 2G EGFR-TKIs. Additionally, with the use of osimertinib, fewer T790M mutations are being detected as T790M is not a reported resistance mechanism to 3G EGFR-TKIs. However, there are currently no approved targeted therapies after 3G EGFR-TKIs. In order to further improve patient outcomes, there is a need to explore additional options for the overall treatment strategy for patients, including 1L and beyond. Combination of vascular endothelial growth factor (VEGF) inhibitors and EGFR-TKIs or chemotherapy and EGFR-TKIs may be a potential therapeutic approach in the 1L setting. This review discusses current treatment options for mNSCLC with activating EGFR mutations based on tumor, patient, and treatment characteristics and how an overall treatment plan may be developed.

Keywords: EGFR–tyrosine kinase inhibitor (EGFR-TKI); Non–small-cell lung cancer; disease control rate (DCR); epidermal growth factor receptor; epidermal growth factor receptor (EGFR); exon 19 deletion mutation (ex19del); exon 21 L858R mutation (L858R); first line (1L); median overall survival (mOS); median progression-free survival (mPFS); mutation subtype. Abbreviations: first generation (1G); non–small cell lung cancer (NSCLC); objective response rate (ORR); overall survival (OS); progression-free survival (PFS); second generation (2G); second line (2L); third generation (3G); treatment plan; tyrosine kinase inhibitor; tyrosine kinase inhibitor (TKI); vascular endothelial growth factor (VEGF).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms